This trial is evaluating whether Paclitaxel will improve 1 primary outcome and 2 secondary outcomes in patients with Ovary Cancer. Measurement will happen over the course of through study completion, an average of 1 year.
This trial requires 38 total participants across 2 different treatment groups
This trial involves 2 different treatments. Paclitaxel is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
At least 10% of cases of ovarian cancer may be attributed to hereditary causes. This article discusses genetic syndromes that are associated with an increased risk of ovarian cancer, including hereditary nondisjunction and Turner syndrome, and includes an update on other genetic syndromes listed in the ovarian cancer genetics section under "other risk factors" above.
Ovary cancer patients had few treatments, but there was a low rate of patient dropout because of side effects from treatments. More information on available side effects and treatment-related symptoms from patients, doctors, and caregivers should be presented.
Most women will respond well to surgery; some will be cured by the surgery. In the long term, a sizeable proportion will experience relapse. Future studies assessing the timing of surgical intervention, duration of surgery and chemotherapy are required to evaluate cure rates.
Ovary cancers are rare and are more common in women of older age. Ovary cancers make up approximately 10 per cent of all ovarian malignancies. The average age at diagnosis is 55. The most common subtype of ovarian cancer is serous ovarian cancer, which accounts for more than 90 per cent of ovarian cancers. Most women who present with an ovarian cancer have stage two disease. The 5-year survival rate with stage two cancer is 63 per cent. The overall stage is the most important indicator of prognosis. The 5-year survival rate is 68 per cent for stage one and 59 per cent for stage two tumors.
The only symptom of ovarian cancer that can be reliably identified is painless, unilateral lump in the ovary or fallopian tube. The diagnosis of ovarian cancer by palpation alone is extremely unreliable because the testicles often present with a hard mass. However, this test should be repeated prior to removing the ovary, since this may cause the lump to disappear or become softer and more cystic. Painless metastases to other organs should also be considered as a cause of ovarian cancer. Sixty percent to seventy-five percent of patients with ovarian cancer will have a family member with an ovarian cancer history. The ovarian cancer patient must have a complete evaluation before making any decisions regarding surgery.
Ovarian cancer is the ninth leading cause of women's deaths during their lifetime. In women, the leading cause of ovarian cancer is pelvic inflammatory disease and has declined since the 1980s due to improvements in screening and treatment.
Our research shows that in order to find new treatments for ovarian cancer, researchers have taken on a plethora of new drugs to test on patient samples. We can see the promise, but also are there any possible side effects from these treatments? question: Is it possible to diagnose pre-cancerous (hyperplastic) lesions in uterine endometrium? answer: The most important point for pre-cancerous lesions diagnosis in uterine endometrium is not to use invasive techniques, but rather to select appropriate sampling technique. There are many cases where pre-cancerous lesions are misdiagnosed as carcinoma in situ. Hence, it is important to exclude benign from borderline epithelia.
Paclitaxel is active in combination chemotherapy, with or without fluorouracil. However, the combination of paclitaxel and docetaxel has not been evaluated in the metastatic setting to date. Given the active role of paclitaxel in metastatic breast cancer in the nonnude mouse model, it may be of reasonable usefulness in metastatic ovarian cancer. Paclitaxel appears to be active in both the neoadjuvant setting, as well as in the metastatic setting.
Despite a relatively low incidence of ovarian epithelial cancers, early detection and treatment of ovarian cancer is essential. The disease may be asymptomatic, but when symptoms do occur, they are non-specific with many other conditions that are more common. The best screening test for this cancer is ultrasounds once a year with the CA125 tumour marker. The best treatment is cytoreductive surgery (removing as many cancer cells as possible) with or without paclitaxel. Most advanced carcinoma of the ovary is stage 3 and in these patients, systemic chemotherapy is warranted. On the basis of these studies, it is estimated that approximately 2500 ovary cancer cases occur in the UK and 3000 cases in the USA each year.
The most common side effects of paclitaxel include [peripheral neuropathy](https://www.withpower.com/clinical-trials/peripheral-neuropathy), fatigue, and anorexia. Other side effects include nausea, hair loss, skin rash, muscle weakness, and constipation. There are very few side effects specifically caused by paclitaxel.
The average age of diagnosis for stage I and II ovarian cancer is approximately 45 years. For stage III and IV disease, the average interval from diagnosis to death is 3.0 years. This is nearly 2 years earlier than the average interval of 1-year survival for stage I and II Disease.
The majority of women who were studied responded positively to PTX, demonstrating excellent QoL. The most common adverse side effects reported were pain, bleeding, and GI irritation. In a recent study, findings suggest that PTX is well tolerated and, therefore, should be considered for further testing in this setting.